Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944629 · ClinicalTrials.gov registry record
Efficacy of Arnica Montana in Reducing Postoperative Edema and Pain
A clinical trial, sponsored by Tufts University.
- Completed
- Registry status
- 53
- Enrollment target
NCT03944629: Completed study, sponsored by Tufts University.
NCT03944629 is a clinical trial that has completed, run by Tufts University. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03944629 has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
Study Summary
This study is a prospective, randomized, double-blinded, controlled, clinical trial that evaluates the efficacy of using high potency homeopathic Arnica montana (SinEcch™) during the perioperative period for decreasing swelling and pain after extraction of partial or full/complete bony impacted third molars. The study group will be comprised of subjects who will receive homeopathic Arnica montana (SinEcch™) for perioperative management of edema and pain. The control group will be comprised of subjects who will receive matching SinEcch™ placebo (sugar pill).
Primary Outcome
Primary outcome is the change in postoperative facial swelling volume as measured by the 3dMD™ system
Interventions
- OTHER Placebo
- DRUG SinEcch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2022-06-14 |
What the finished NCT03944629 record still lists
NCT03944629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03944629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03944629 about?
NCT03944629 is a clinical study titled "Efficacy of Arnica Montana in Reducing Postoperative Edema and Pain". This study is a prospective, randomized, double-blinded, controlled, clinical trial that evaluates the efficacy of using high potency homeopathic Arnica montana (SinEcch™) during the perioperative period for decreasing swelling and pain after extraction of partial or full/complete bony impacted thir...
What is the current status of trial NCT03944629?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2018-01-26. Estimated completion is 2022-06-14.
What interventions are being tested in trial NCT03944629?
The interventions under investigation include: Placebo (OTHER), SinEcch (DRUG).
Who is sponsoring clinical trial NCT03944629?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI